{"product_id":"cartalax-peptide-joint-cartilage-research","title":"Cartalax Peptide - Joint \u0026 Cartilage Research","description":"\u003ch3\u003e\u003cstrong\u003eMechanism of Action of Cartalax (AED Tripeptide) at the Molecular Level and Clinical Effects\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCartalax is the synthetic tripeptide with the amino acid sequence Ala-Glu-Asp (AED). Its molecular weight is 333.29 Da, and its CAS number is 205640-90-0.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCartalax, the synthetic tripeptide Ala-Glu-Asp (AED), is a short-chain cytogen developed as a tissue-specific bioregulator with pronounced affinity for cells of the cartilage and connective tissue, including chondrocytes and skin fibroblasts. Its exceptionally small size (molecular weight 333.29 Da) enables it to readily cross cellular membranes, penetrate the nucleus without requiring receptor-mediated endocytosis or classical surface signaling pathways, and exert direct effects on nuclear components.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eOnce inside the cell, AED localizes primarily to the nucleoplasm and nucleolus, where it modulates gene expression through direct interaction with DNA and chromatin structures rather than through conventional second-messenger systems.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eDNA Binding and Epigenetic Regulation\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eThe core molecular mechanism of Cartalax involves sequence-specific binding to double-stranded DNA.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBiophysical studies and molecular docking have identified a preferred binding motif for the AED tripeptide: the tetranucleotide ACCT sequence located in the promoter regions of genes critical for cartilage matrix synthesis, cell proliferation, and connective tissue homeostasis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBinding occurs preferentially in GC-rich regions and leads to local destabilization of the DNA double helix. This interaction sterically hinders repressive chromatin complexes and prevents inhibitory methylation, thereby maintaining promoters in a transcriptionally active, euchromatic state.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn addition to direct DNA interaction, Cartalax modulates chromatin architecture by promoting deheterochromatinization. The tripeptide induces conformational changes that increase the proportion of transcriptionally active euchromatin while reducing condensed heterochromatin, particularly in aging chondrocytes and fibroblasts.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis epigenetic remodeling reactivates genes that are progressively silenced during biological aging, significantly enhancing accessibility of transcription factors to target promoters without altering the underlying DNA sequence.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis process represents a classic example of epigenetic regulation, allowing Cartalax to restore youthful patterns of gene expression in senescent cells.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eKey Target Genes and Cellular Effects\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eKey target genes regulated by AED binding in their promoter regions include those involved in:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Extracellular matrix synthesis — collagen type II (COL2A1), aggrecan, proteoglycans, and SOX9 — leading to enhanced production of cartilage structural components;\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Proliferation markers such as PCNA and Ki67 — supporting chondrocyte division and tissue remodeling;\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Senescence and apoptosis regulators p16, p21, and p53 — whose expression is downregulated under stress conditions;\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e• Matrix metalloproteinases (MMPs, including MMP-13) and inflammatory enzymes — whose activity is suppressed to help limit cartilage degradation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eFurthermore, Cartalax upregulates genes supporting connective tissue integrity and differentiation in both cartilage and skin fibroblast models, promoting balanced matrix remodeling and cellular resilience.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eEffects Under Stress and Aging Conditions\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eUnder conditions of oxidative, inflammatory, or age-related stress (such as osteoarthritis models, replicative senescence, or cartilage explant cultures), Cartalax finely modulates proliferative and reparative signaling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt accelerates the transition of chondrocytes into active proliferative phases while preventing excessive apoptosis and senescence. This temporal control helps restore cartilage competence and limits premature cellular aging.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSimultaneously, Cartalax shifts the intracellular balance strongly toward survival, repair, and functional maintenance.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCartalax demonstrates strong tissue specificity toward cartilage and connective tissue (chondrocytes, fibroblasts), showing minimal activity in unrelated cell types due to the selective distribution of its DNA-binding motifs and chromatin partners in these tissues.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003ePost-Transcriptional and Translational Regulation\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eBiophysical studies suggest that Cartalax may also interact with nuclear ribonucleoprotein complexes, stabilizing mRNA transcripts of the upregulated genes and improving translational efficiency.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis multi-level regulation — encompassing direct DNA binding, chromatin deheterochromatinization, proliferation support, matrix synthesis enhancement, and post-transcriptional stabilization — creates a comprehensive molecular program that restores cartilage homeostasis, extracellular matrix balance, and connective tissue resilience.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eClinical Effects and Research Applications\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAt the observational level, Cartalax demonstrates pronounced chondroprotective, regenerative, and geroprotective properties that translate its molecular epigenetic actions into measurable improvements in joint function, cartilage integrity, and connective tissue resilience.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt is being investigated in research protocols focused on degenerative joint changes associated with aging, osteoarthritis models, post-traumatic states, and prolonged mechanical stress.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCartalax significantly supports joint health and cartilage remodeling processes. Experimental observations and preclinical studies consistently demonstrate stimulation of chondrocyte proliferation, increased synthesis of cartilage matrix components (collagen type II and aggrecan), and preservation of cartilage tissue architecture.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn osteoarthritis and age-related cartilage degeneration models, it helps normalize the balance between matrix formation and matrix breakdown, supporting improved structural and functional outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eAnti-Inflammatory and Tissue-Supportive Effects\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eThe peptide exhibits strong anti-inflammatory and tissue-supportive effects in musculoskeletal research settings.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBy downregulating degradative enzymes and senescence markers while promoting reparative signaling programs, it helps reduce cartilage breakdown, modulate inflammatory activity, and support recovery following mechanical stress or tissue injury.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eObservational reports have noted improvements in joint comfort, flexibility, mobility, and physical performance parameters.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eA consistent and well-documented observational finding is support for joint comfort and functional mobility.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn individuals with osteoarthritis-associated or age-related joint changes, adjunctive research use of Cartalax has been associated with reductions in discomfort intensity, improved joint stability, and enhanced quality-of-life measures, often becoming noticeable during structured observation periods.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eGeroprotective and Healthy Aging Effects\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCartalax demonstrates clear geroprotective (healthy-aging-supportive) effects on cartilage and connective tissue.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIt helps slow biological aging processes by protecting chondrocytes from accumulated oxidative and inflammatory stress, maintaining epigenetic regulation, and supporting extracellular matrix production.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn aging populations, it may help counteract cartilage thinning, reduced elasticity, and progressive joint degeneration.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eContinued research exposure has been associated with preservation of musculoskeletal function, joint flexibility, and physical independence over time.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eExperimental Findings and Safety Profile\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eAdditional observed benefits include accelerated connective tissue recovery following joint stress or surgical intervention models and broader improvements in connective tissue resilience.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eStudies in cartilage explant cultures and animal models confirm increased cartilage area index, elevated proliferation markers (PCNA), and reduced senescence\/apoptosis-associated markers (p53).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCartalax is characterized by excellent tolerability and a favorable safety profile, with minimal adverse effects reported aside from rare individual hypersensitivity reactions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese observed outcomes are closely linked to its molecular actions on gene expression, chromatin remodeling, extracellular matrix synthesis, anti-senescence pathways, and chondrocyte regeneration, positioning it as a targeted bioregulator for cartilage support, connective tissue resilience, and healthy musculoskeletal aging research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan style=\"font-kerning: none;\"\u003eRead more about cartilage bioregulator peptides and their relationship to connective tissue signaling and extracellular matrix support.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan style=\"font-kerning: none;\"\u003e→\u003ca href=\"https:\/\/www.peptideregenesis.com\/blogs\/peptide-blog\/what-are-bioregulators\"\u003e\u003cspan\u003eWhat Are Bioregulator Peptides?\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLearn more about how Cartalax compares to BPC-157 and TB-500 in our detailed regenerative peptide comparison guide exploring cartilage repair, tissue healing, and joint recovery pathways.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan style=\"font-kerning: none;\"\u003e→ \u003c\/span\u003e\u003ca href=\"https:\/\/www.peptideregenesis.com\/blogs\/peptide-blog\/cartalax-vs-bpc-157-vs-tb-500\"\u003eCartalax vs BPC-157 vs TB-500\u003c\/a\u003e\u003c\/strong\u003e \u003c\/p\u003e","brand":"PRG","offers":[{"title":"Capsules","offer_id":53090024751370,"sku":null,"price":140.0,"currency_code":"EUR","in_stock":true},{"title":"Vial","offer_id":53090024784138,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":false},{"title":"Pre-filled Pen","offer_id":53090024816906,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0908\/7113\/6522\/files\/CARTALAX1.png?v=1779456903","url":"https:\/\/www.peptideregenesis.com\/it\/products\/cartalax-peptide-joint-cartilage-research","provider":"PRG","version":"1.0","type":"link"}